Patents by Inventor Laura Sue Grosmaire
Laura Sue Grosmaire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200354447Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: December 23, 2019Publication date: November 12, 2020Inventors: Peter Armstrong THOMPSON, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Laura Sue GROSMAIRE, Robert BADER, William BRADY
-
Publication number: 20190290755Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition; the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: October 26, 2018Publication date: September 26, 2019Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Patent number: 10143748Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: GrantFiled: March 15, 2013Date of Patent: December 4, 2018Assignee: Aptevo Research and Development LLCInventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Publication number: 20180118823Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: June 8, 2017Publication date: May 3, 2018Applicant: APTEVO RESEARCH AND DEVELOPMENT LLCInventors: Peter Armstrong THOMPSON, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Laura Sue GROSMAIRE, Robert BADER, William BRADY
-
Publication number: 20140141022Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: March 15, 2013Publication date: May 22, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
-
Publication number: 20140127203Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: March 15, 2013Publication date: May 8, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
-
Publication number: 20140072562Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Applicant: Emergent Product Development Seattle, LLCInventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Publication number: 20140010813Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: March 15, 2013Publication date: January 9, 2014Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Publication number: 20140004117Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: March 15, 2013Publication date: January 2, 2014Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Publication number: 20130266561Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Patent number: 8409577Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: GrantFiled: June 12, 2007Date of Patent: April 2, 2013Assignee: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
-
Publication number: 20120034245Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: June 12, 2007Publication date: February 9, 2012Applicant: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
-
Publication number: 20110158995Abstract: This disclosure provides a multi-specific fusion protein composed of a CD72-ligand binding domain and another binding domain specific for a heterologous target, such as a B-cell specific protein. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: ApplicationFiled: July 28, 2009Publication date: June 30, 2011Applicant: RENAULT S.A.SInventors: Philip Tan, Laura Sue Grosmaire, Peter Robert Baum, Peter Armstrong Thompson
-
Publication number: 20110033483Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: June 12, 2007Publication date: February 10, 2011Applicant: Trubion Pharmaceuticals Inc.Inventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
-
Publication number: 20100330089Abstract: The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.Type: ApplicationFiled: June 12, 2008Publication date: December 30, 2010Applicants: Wyeth, Trubion Pharmaceuticals Inc.Inventors: Nitin K. Damle, Lioudmila Tchistiakova, Kyriaki Dunussi-Joannopoulos, Sandy Alexander Simon, William Brady, Laura Sue Grosmaire, Jeffrey Alan Ledbetter